Topic: multiple sclerosis
European regulators are recommending an immediate suspension and recall of AbbVie and Biogen multiple sclerosis drug Zinbryta.
It was a short run, but Biogen and AbbVie’s multiple sclerosis-fighter Zinbryta is coming off markets around the globe.
Putting digital into Novartis' DNA is one of CEO Vas Narasimhan’s goals, and the drugmaker has just inked another deal that aims to do just that.
Celgene's MS candidate ozanimod might have challenged some big blockbusters in the field, but an FDA decision means it won't happen anytime soon.
Novartis’ copycat arm, Sandoz, needed a win. And it got a key one Tuesday with the approval of generic 40-mg Copaxone.
Mylan’s long-acting Copaxone copy won FDA approval just three months ago, but it’s already gobbled up a sizable chunk of Teva’s market share.
Just two days after Mylan won FDA approval for its long-acting Copaxone generic, Mylan’s European partner got a green light, too.
Mylan’s long been frustrated by generics delays. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense.
Rep. Elijah Cummings, D-Md., is urging President Trump to press for lower prices on Biogen's multiple sclerosis drug Zinbryta.
Merck KGaA has won European approval for its oral MS drug, but competing with more established rivals won't be easy.